The pharmaceutical industry faces significant challenges as Novo Nordisk and Eli Lilly grapple with trial setbacks and market ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Second, the company could make significant clinical progress next year. Novo Nordisk has several late-stage programs in ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of ...

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after ...

In November, NVO shares crossed into a long-term bear market as they fell below their 20-month moving average - a key ...

Novo Nordisk faces scrutiny after disappointing trial results for CagriSema, a next-gen obesity drug, caused a significant market valuation drop. Analysts question whether side effects limited dosage ...